|
WO2019043245A1
|
|
Microbial cells expressing streptococcal serotypes
|
|
CN110418649A
|
|
Whole-cell vaccines
|
|
US2020054732A1
|
|
Francisella glycoconjugate vaccines
|
|
GB201714128D0
|
|
Glycoconjugate
|
|
GB201704103D0
|
|
Whole cell vaccine
|
|
GB201704117D0
|
|
Oligosaccharyl Transferase polypeptide
|
|
GB201704108D0
|
|
Whole cell vaccines
|
|
GB201620486D0
|
|
Oligosaccharyl transferase polypeptide
|
|
GB201603963D0
|
|
Whole cell vaccine
|
|
GB201603958D0
|
|
Whole cell vaccines
|
|
GB201603948D0
|
|
Oligosaccharyltransferase polypeptide
|
|
GB201516109D0
|
|
Therapeutic agent
|
|
GB201514002D0
|
|
Francisella glycoconjugate vaccines
|
|
GB201504915D0
|
|
Ophthalmoscope
|
|
GB201418283D0
|
|
Production of anti-microbial peptides
|
|
GB201418135D0
|
|
Anti-viral agent
|
|
AU2014218463A1
|
|
Baculoviral vectors
|
|
GB201410060D0
|
|
Multivalent and monovalent vaccines
|
|
GB201408699D0
|
|
Nutritional supplementation
|
|
WO2014111724A1
|
|
Glycosylation method
|
